Biologics Price Competition and Innovation Act

Target entity: Biologics Price Competition and Innovation Act
Context triple: [Drug Price Competition and Patent Term Restoration Act of 1984, relatedTo, Biologics Price Competition and Innovation Act]

• A. Food and Drug Administration Amendments Act of 2007
  The Food and Drug Administration Amendments Act of 2007 is a U.S. law that expanded the FDA’s authority over drug and device safety, clinical trials, and post-market surveillance, while enhancing transparency and user fee programs.
• B. Drug Price Competition and Patent Term Restoration Act of 1984
  The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, is a U.S. law that streamlined the approval of generic drugs while providing patent term extensions to brand-name drug manufacturers to balance innovation and competition.
• C. 21st Century Cures Act
  The 21st Century Cures Act is a U.S. federal law enacted in 2016 that accelerates medical product development and innovation, expands funding for biomedical research and mental health services, and modernizes the regulation of drugs and medical devices.
• D. Prescription Drug User Fee Act of 1992
  The Prescription Drug User Fee Act of 1992 is a U.S. law that authorizes the FDA to collect fees from pharmaceutical companies to fund and expedite the review of new drug applications.
• E. Medicare Prescription Drug, Improvement, and Modernization Act of 2003
  The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 is a major U.S. federal law that overhauled Medicare by adding outpatient prescription drug coverage and expanding private plan options for beneficiaries.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Target entity: Biologics Price Competition and Innovation Act
Target entity description: The Biologics Price Competition and Innovation Act is a U.S. law that created an abbreviated regulatory pathway for approval of biosimilar and interchangeable biological products to promote competition while balancing incentives for innovation.

• A. Food and Drug Administration Amendments Act of 2007
  The Food and Drug Administration Amendments Act of 2007 is a U.S. law that expanded the FDA’s authority over drug and device safety, clinical trials, and post-market surveillance, while enhancing transparency and user fee programs.
• B. Drug Price Competition and Patent Term Restoration Act of 1984
  The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, is a U.S. law that streamlined the approval of generic drugs while providing patent term extensions to brand-name drug manufacturers to balance innovation and competition.
• C. 21st Century Cures Act
  The 21st Century Cures Act is a U.S. federal law enacted in 2016 that accelerates medical product development and innovation, expands funding for biomedical research and mental health services, and modernizes the regulation of drugs and medical devices.
• D. Prescription Drug User Fee Act of 1992
  The Prescription Drug User Fee Act of 1992 is a U.S. law that authorizes the FDA to collect fees from pharmaceutical companies to fund and expedite the review of new drug applications.
• E. Medicare Prescription Drug, Improvement, and Modernization Act of 2003
  The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 is a major U.S. federal law that overhauled Medicare by adding outpatient prescription drug coverage and expanding private plan options for beneficiaries.
• F. None of above. chosen